Development-ready generic dossiers, with every fact carrying provenance
Lawsone is a dossier production platform: an in-house agent pipeline turns public regulatory records into complete, licensable formulation dossiers for marketed drugs - master formula, manufacturing procedure, specifications, and equivalence evidence, validated by simulation. You license the dossier; you skip the guesswork.
One line gets you the non-confidential dossier index. Replies come from the dossier's author, usually within 48 h. Write to aws@lawsone.si.
Section 1 · Current assets / details under NDA
20 mg immediate-release tablet. Candidate master formula plus granulation process and specifications on standard equipment; no special infrastructure required. Simulation-supported equivalence; documented failure-mode analysis included.
145 mg nanocrystal tablet requiring wet bead-milling. Full quantitative recipe confirmed across three regulatory regions; mill parameters, stabilizer system, and discriminating dissolution design included.
| Asset | Class | Status |
|---|---|---|
| LW-A | Immediate-release oral solid, conventional process | Licensable |
| LW-B | Nanocrystal tablet, wet bead-milling platform | Licensable |
| LW-C | Amorphous solid dispersion, tablet | Licensable |
| LW-D | Amorphous solid dispersion, softgel and tablet | Licensable |
| LW-E | Lipid-based softgel | Licensable |
| LW-F | Hard capsule plus intravenous form | Licensable |
| LW-G | Permeation-enhanced oral tablet, peptide | Licensable |
Section 2 · The provenance standard
Every figure in a Lawsone dossier carries a confidence tag. You always know what is established and what is inference, so your regulatory and legal teams can diligence the file line by line instead of trusting a black box.
We never claim the innovator's confidential manufacturing record. What we deliver is a defensible point inside the equivalence region: a candidate formula and process whose every number is graded — verified, inferred, or flagged to test in your first batch.
| Claim | Tag | Value |
|---|---|---|
| Reference-product dissolution profile, all compendial media | Verified | |
| Excipient grades and supplier class | Verified | |
| Target binder and disintegrant levels, % w/w | Inferred | |
| Critical process parameter windows | Hypothesized | |
| Optimal Trial-1 batch size for pilot-BE | Hypothesized |
Section 3 · What a license includes
- Master formula: per-unit and per-batch, with excipient grades and suppliers
- Manufacturing procedure: CPPs, in-process controls, scale-up notes
- Specifications: API and excipient specs, each provenance-tagged
- Equivalence evidence: dissolution rationale plus simulation package
- Robustness screen: Monte-Carlo sensitivity on critical parameters
- Pilot-BE appendix: study design for a fasted pilot bioequivalence trial
Section 4 · Engagement
Non-confidential overview: asset class, dossier depth, licensing terms.
Mutual NDA, then compound identity plus the stage-1 data pack.
Your team reviews the dossier line by line: provenance map, dissolution overlays, robustness report.
Territorial license: upfront, milestones, profit share. Formula under signature.
Section 5 · Commission a dossier / any molecule
The licensed assets above are what is ready today. The desk also builds dossiers to order: name the molecule, dosage form, and target markets, and we scope feasibility, timeline, and price before you commit to anything.
Best fits: oral solids on conventional equipment, nanocrystal and amorphous-dispersion products, lipid and softgel fills, and reference products with hard-to-read formulations. Send the request; a feasibility answer comes back within a few days.